About
This combination medication integrates the therapeutic benefits of a DPP-4 inhibitor (e.g., Teneligliptin) with Metformin, providing a comprehensive and synergistic approach to the management of type 2 diabetes mellitus. The DPP-4 inhibitor component works by preventing the degradation of incretin hormones, such as GLP-1 and GIP, which are naturally released after meals. This leads to enhanced glucose-dependent insulin secretion from the pancreas and a reduction in glucagon release, thereby improving postprandial glucose control. Concurrently, Metformin, a well-established biguanide, exerts its effects primarily by decreasing glucose production in the liver, reducing glucose absorption from the intestines, and improving the body's sensitivity to insulin in peripheral tissues. This dual mechanism addresses multiple underlying pathophysiological defects characteristic of type 2 diabetes, offering superior glycemic control compared to monotherapy with either agent alone. The fixed-dose combination simplifies treatment regimens, potentially improving patient adherence, and is particularly beneficial when initial monotherapy is insufficient to achieve target blood glucose levels, providing robust efficacy with a generally well-tolerated profile.
Uses
- Management of type 2 diabetes mellitus in adults.
- When diet and exercise alone are insufficient.
- When monotherapy with either metformin or a DPP-4 inhibitor is inadequate.
- To improve glycemic control in patients already on both medications separately.
Directions For Use
Take orally, usually with meals, as directed by your healthcare provider. Do not crush or chew tablets.
Benefits
- Comprehensive blood glucose control.
- Targets multiple pathways of diabetes.
- Improved efficacy compared to monotherapy.
- Convenient fixed-dose combination.
- Lower risk of hypoglycemia compared to sulfonylureas.
- May contribute to weight stability or modest weight loss.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Nasopharyngitis
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare, due to metformin)
- Pancreatitis (rare, due to DPP-4 inhibitor)
- Joint pain
- Skin rash
Safety Measures
- Alcohol - Avoid excessive alcohol intake due to increased risk of lactic acidosis (from metformin component) and potential effects on blood sugar.
- Pregnancy - Consult your doctor. Generally not recommended during pregnancy; insulin is often preferred. Discuss risks and benefits.
- Breastfeeding - Not recommended. Both components may pass into breast milk. Consult a healthcare professional to weigh risks to the infant versus benefits to the mother.
- Liver - Use with caution in patients with impaired liver function due to the metformin component, which increases lactic acidosis risk. Not recommended in severe hepatic impairment.
- Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment is required for moderate renal impairment due to metformin.
- Lung - Generally safe, but severe respiratory failure can increase the risk of lactic acidosis due to the metformin component.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!